Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05875441 | COMPLETED | Scabies

Efficacy and Safety Study of Moxidectin in Adults With Scabies
Sponsor:

Medicines Development for Global Health

Brief Summary:

Moxidectin is not approved to treat scabies in humans. The effective dose of moxidectin to treat scabies is not known. This study aims to assess the efficacy of a single administration of 8 mg, 16 mg, or 32 mg moxidectin per oral in achieving Scabies Complete Cure at Day 28. This study also aims to assess the safety of three strengths of single moxidectin doses in adults with scabies.

Condition or disease

Scabies

Intervention/treatment

Moxidectin Oral Product

Moxidectin Oral Product

Moxidectin Oral Product

Placebo

Phase

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 200 participants
Masking : QUADRUPLE
Masking Description : Double blinded. Subjects will be randomized to one of the treatment arm by Interactive Response Technology at 1:1:1:1
Primary Purpose : TREATMENT
Official Title : A Phase 2, Placebo-controlled, Double-blind, Randomized, Dose Ranging, Efficacy and Safety Study of Orally Administered Moxidectin in Adults With Scabies.
Actual Study Start Date : 2023-11-23
Estimated Primary Completion Date : 2024-11-27
Estimated Study Completion Date : 2025-02-11

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Aged 18 years or older.
  • 2. Provided written informed consent.
  • 3. Diagnosis of active scabies infestation confirmed by the presence of clinical signs and symptoms (evidence of burrows or typical inflammatory/noninflammatory lesions and pruritus) and either microscopic confirmation of scabies mite(s), ova or scybala by skin scraping or dermoscopy.
  • 4. All female subjects of childbearing potential must agree to the use of a highly effective method of birth control until 16 weeks after administration of Investigational Product (IP).
Exclusion Criteria
  • 1. Diagnosis of crusted/Norwegian scabies or scabies presentation that, in the opinion of the Investigator, would require treatment with more than one standard of care treatment for scabies (e.g., scabies requiring concurrent topical and oral treatment).
  • 2. History of chronic or recurrent dermatologic disease or skin conditions other than scabies that could interfere with the diagnosis of scabies and evaluation of cure.
  • 3. Received any treatment with one or more scabicides within the 28 days prior to Screening, or between Screening and Baseline, including but not limited to permethrin, ivermectin, benzyl benzoate, sulfur, lindane, crotamiton, malathion, tea tree oil or spinosad.
  • 4. Body mass index \> 35 kg/m2.
  • 5. Creatinine clearance \< 30 mL/min (using Cockcroft-Gault equation).
  • 6. Both total bilirubin \>1.5 x upper limit of normal (ULN) and AST \> ULN.
  • 7. Abnormal and clinically relevant findings in hematology or biochemistry assessments at Screening, or in vital signs, 12-lead ECG, or physical examination at Screening and/or Baseline, that in the opinion of the Investigator would put the subjects at increased risk from participating in the study, confound study evaluations, or may interfere with study conduct.
  • 8. Presence of any other clinically relevant condition, including infection, immunological disorder, malignant disease, and/or other underlying condition or circumstance at Screening or Baseline that in the opinion of the Investigator would put the subjects at increased risk from participating in the study, confound study evaluations, or interfere with the study conduct.
  • 9. Use of topical steroids, systemic or high-dose inhaled corticosteroids (\>500 µg per day of fluticasone propionate or equivalent for adults), or other immunomodulators within 14 days of Baseline.
  • 10. Requiring ongoing treatment with, or received within 5 half-lives before Screening, any of the following medications that are clinical BCRP inhibitors: curcurmin (turmeric) supplements, cyclosporine A, darolutamide, eltrombopag, febuxostat, fostamatinib, rolapitant and teriflunomide.
  • 11. Received an investigational agent within 28 days of Screening (or 5 half-lives of the investigational agent, whichever is longer).
  • 12. Known or suspected hypersensitivity to macrocyclic lactones or excipients used in the formulation of moxidectin or ivermectin.
  • 13. Known or suspected hypersensitivity to any of the components in permethrin 5% cream, to any synthetic pyrethroid or pyrethrin, or to the components of spinosad 0.9% topical suspension.
  • 14. Known, suspected or at risk of Loa loa coinfection.
  • 15. Difficulty swallowing tablets or capsules.
  • 16. Pregnant or breastfeeding or planning to become pregnant from Screening until 16 weeks after treatment with IP.
  • 17. Known or suspected alcohol or illicit substance abuse.
  • 18. Unwilling, unlikely or unable to comply with all protocol specified assessments.
  • 19. Previous enrolment in this study.
  • 20. Previous moxidectin exposure within 6 months (5 half-lives) from Baseline.
  • 21. Has household members who refuse or are unable to receive permethrin 5% cream treatment for scabies.
Efficacy and Safety Study of Moxidectin in Adults With Scabies

Location Details

NCT05875441

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United States, California

LA Universal Research Center, Inc

Los Angeles, California, United States, 90057

Not yet recruiting

United States, Florida

Evolution Clinical Trials

Miami, Florida, United States, 33016

Not yet recruiting

United States, Florida

Advanced Care and Clinical Trials, LLC

Miami, Florida, United States, 33155

Not yet recruiting

United States, Florida

Medical Research of Westchester, Inc

Miami, Florida, United States, 33165

Not yet recruiting

United States, Florida

Affinity Clinical Research LLC

Tampa, Florida, United States, 33612

Not yet recruiting

Dominican Republic, Santo Domingo

Dominican Dermatological Institute and Leather Surgery

SANTO SUNDAY WEST, Santo Domingo, Dominican Republic,

Not yet recruiting

El Salvador,

Vargas Clinic

San Salvador, El Salvador, 01101

Not yet recruiting

Honduras, Cortes

Hospital and Clinic Blessed

San Pedro Sula, Cortes, Honduras, 21104

Not yet recruiting

Honduras, Cortez

Derclinic

San Pedro Sula, Cortez, Honduras, 21104